Files and links (1)
Accepted (AM)Open Access (License Unspecified), Open
Journal article
The CombiRx trial of combined therapy with interferon and glatiramer acetate in relapsing remitting MS: Design and baseline characteristics
Multiple sclerosis and related disorders, v 1(2), pp 81-86
Apr 2012
PMID: 25876935
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Interferon-β1a (IFNB) and glatiramer acetate (GA) are distinct therapies which are both partially effective for relapsing MS. It is not known if combining the two treatments would be more effective.
To review the rationale, design, and baseline characteristics of the CombiRx study of combined treatment with IFNB and GA.
The key inclusion criteria included a diagnosis of relapsing MS, at least 2 episodes of MS activity in the previous 3 years, expanded disability status scale of 0–5.5, and no prior treatment with either IFNB or GA. Subjects were randomized to IFNB+GA, IFNB monotherapy, or GA monotherapy in a 2:1:1 ratio.
From 2005 to 2009, we enrolled 1008 subjects. The participants were 72.4% female and 87.6% Caucasian with a mean age of 37.7 years. The median duration of symptoms was 2 years at entry into the study, and the mean EDSS was 2.1. On the baseline MRI, the mean total lesion load was 12.2ml, and 40% of the participants had enhancing lesions.
We have recruited a population of patients with clinical and MRI characteristics typical for early MS. The study results will aid in deciding on the optimum early treatment. This trial should serve as a model for future studies of combination therapy.
► Available therapies for MS are only partially effective. ► Combining therapies might be more effective. ► We compared the combination of interferon and glatiramer to either agent alone. ► We present the baseline characteristics of our study population.
Metrics
Details
- Title
- The CombiRx trial of combined therapy with interferon and glatiramer acetate in relapsing remitting MS: Design and baseline characteristics
- Creators
- J.W. Lindsey - The University of Texas Health Science Center at HoustonT.F. Scott - Drexel UniversityS.G. Lynch - University of Kansas Medical CenterS.S. Cofield - University of Alabama at BirminghamF. Nelson - The University of Texas Health Science Center at HoustonR. Conwit - National Institute of Neurological Disorders and StrokeT. Gustafson - Corinne Goldsmith Dickinson Center for Multiple SclerosisG.R. Cutter - University of Alabama at BirminghamJ.S. Wolinsky - The University of Texas Health Science Center at HoustonF.D. Lublin - Corinne Goldsmith Dickinson Center for Multiple Sclerosisfor the CombiRx Investigators Group
- Publication Details
- Multiple sclerosis and related disorders, v 1(2), pp 81-86
- Publisher
- Elsevier
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Neurology
- Web of Science ID
- WOS:000209275900007
- Scopus ID
- 2-s2.0-84857714278
- Other Identifier
- 991019167666504721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- Web of Science research areas
- Clinical Neurology